NCT02813408 (AQUARiUS) is a clinical trial in Prostatic Neoplasms, sponsored by Janssen Pharmaceutica N.V., Belgium.

Who is sponsoring NCT02813408?

NCT02813408 is sponsored by Janssen Pharmaceutica N.V., Belgium.

What condition does NCT02813408 study?

NCT02813408 studies Prostatic Neoplasms.

Is NCT02813408 still recruiting?

NCT02813408 is currently completed. Last updated 24 May 2019.

Last reviewed 2019-05-24 · How we verify

NCT02813408: AQUARiUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants

Completed Last updated 24 May 2019

What this trial tests

trial in Prostatic Neoplasms in 226 participants. Completed in 21 March 2018.

Timeline

3 May 2016

Primary endpoint
21 March 2018

21 March 2018

Quick facts

Lead sponsor	Janssen Pharmaceutica N.V., Belgium
Status	Completed
Study type	OBSERVATIONAL
Enrollment	226
Start date	3 May 2016
Primary completion	21 March 2018
Estimated completion	21 March 2018
Sites	26 locations across Denmark, United Kingdom, France

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →

Sponsor

Janssen Pharmaceutica N.V., Belgium — full company profile →

Who can join

18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational study of metastatic castration-resistant prostate cancer (mCRPC) participants is to explore whether or not there are differences between participants treated with abiraterone acetate and enzalutamide on the health-related quality of life (HRQoL), Fatigue, Pain, Cognitive function and medical resource use (MRU).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, et al · · 2020 · cited 44× · PMID 31594705 · DOI 10.1016/j.eururo.2019.09.019
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, et al · · 2018 · cited 31× · PMID 30116592 · DOI 10.1136/esmoopen-2018-000397
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors.
Wefel JS, Ryan CJ, Van J, Jackson JC, et al · · 2022 · cited 9× · PMID 35522374 · DOI 10.1007/s40263-022-00913-5
Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.
El-Amm J, Nassabein R, Aragon-Ching JB. · · 2017 · cited 4× · PMID 28744160 · DOI 10.2147/cmar.s139305

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Janssen Pharmaceutica N.V., Belgium trials

Trials by the same sponsor.

NCT06544616 — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease · Phase 2 · active not recruiting
NCT05706753 — A Study of Milvexian in Healthy Adult Females · Phase 1 · completed
NCT05550519 — A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatm · EARLY_PHASE1 · withdrawn
NCT05552196 — A Study of Ponesimod in Healthy Adult Participants · Phase 1 · completed
NCT05328297 — A Study of JNJ-55308942 in the Treatment of Bipolar Depression · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02813408 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Pharmaceutica N.V., Belgium
Last refreshed: 24 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02813408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing